Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes

Circulating dipeptidyl peptidase 3 – New hope for a specific treatment to improve prognosis in cardiogenic shock?

DPP3 appreciated as promising biomarker for shock diagnosis and shock therapy

The emerging role of dipeptidyl peptidase 3 in pathophysiology

Circulating dipeptidyl peptidase (cDPP3)-A marker for end-stage heart failure?

Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis

High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort.

Circulating dipeptidyl peptidase 3 on intensive care unit admission is a predictor of organ dysfunction and mortality

Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome

Circulating biomarkers to assess cardiovascular function in critically ill

Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage

Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study.

Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.

In-hospital mortality and organ failure after open and endovascular thoraco-abdominal aortic surgery can be predicted by increased levels of circulating dipeptidyl peptidase 3.